Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Additionally, research published in Drug Testing and Analysis characterizing AOD9604 metabolism and confirming its C-terminal HGH fragment structure, supporting its classification as a non-IGF-1-stimulating lipolytic agent has been used by clinicians evaluating the compound for metabolic applications
Certificate of Analysis Each batch is tested by an independent third-party laboratory for: Peptide identity verification Purity analysis via HPLC (99%) Microbial contaminant screening Heavy metal analysis Residual solvent testing Key Ingredients Copper peptide investigated for its effects on dermal papilla cell proliferation and vascular endothelial growth factor (VEGF) expression in scalp and skin tissue
The clinical drug development program was halted in 2007 after the pivotal Phase IIb trial did not show statistically significant weight loss in the primary endpoint
AHK-Cu Studies and Research Data Research on Angiogenesis and Vascular Growth Scientific investigations indicate that AHK-Cu may play a role in modulating angiogenic processes
